Alvotech (ALVO)
(Delayed Data from NSDQ)
$11.89 USD
-0.08 (-0.67%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.86 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALVO 11.89 -0.08(-0.67%)
Will ALVO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALVO
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
ALVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
Other News for ALVO
Alvotech files to sell 1.79M ordinary shares for holders
Alvotech’s Strong Q2 Performance and Positive Outlook Justify Buy Rating
Alvotech (ALVO) Q2 2024 Earnings Call Transcript Highlights: Record Revenues and Positive EBITDA
Bullish Two Hundred Day Moving Average Cross - ALVO
Alvotech (ALVO) Q2 2024 Earnings Call Transcript